Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: A randomized, double-blind, placebo-controlled, proof-of-concept study

Journal of Clinical Psychiatry

Volumn 74, Issue 4, 2013, Pages 363-369

  Montgomery, Stuart A ^a   Mansuy, Lucilla ^b   Ruth, Adam ^c   Bose, Anjana ^d   Li, Hua ^d,e   Li, Dayong ^d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^c Prescott Medical Communications Group   (United States)

^d FOREST RESEARCH INSTITUTE   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DIAZEPAM; GAMMA GLUTAMYLTRANSFERASE; MILNACIPRAN; NEUROLEPTIC AGENT; PLACEBO; ZOLPIDEM; ZOPICLONE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV; FEMALE; HAMILTON SCALE; HEART PALPITATION; HEART RATE; HUMAN; HYPERHIDROSIS; HYPERTENSION; INSOMNIA; INTERVERTEBRAL DISK HERNIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL STRESS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; OPEN FRACTURE; PRIORITY JOURNAL; PROSTATITIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEMINAL VESICLE DISEASE; SHEEHAN DISABILITY SCALE; SIDE EFFECT; SUICIDAL IDEATION; SUSTAINED RELEASE FORMULATION; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREATMENT RESPONSE; XEROSTOMIA;

EID: 84876570587     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12m08141     Document Type: Article

References (29)

1. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burde n of Disease Study. Lancet. 1997;349(9063):1436- 1442.
2. Blier P, Saint-Andre E, Hebert C, et al. Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers. Int J Neuropsychopharmacol. 2007;10(1):41-50.
3. Stahl SM, Grady MM, Moret C, et al. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005;10(9):732-747.
4. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
6. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33, quiz 34-57.
7. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62.
8. Shee han DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(suppl 3):89-95.
9. Guy W. The clinician global severity and impression scales. ECDEU Assessment Man ual for Psychopharmacology. Department of Health, Education, and Welfare publication no. 76- 338. Rockville, MD: National Institute of Mental Health; 1976; 218-222.
10. Lipman R, Covi L. Outpatient treatment of neurotic depression: medication and group psychotherapy. In: Spitzer R, Klein D, eds. Evaluation of Psychological Therapies. Baltimore, MD: John Hopkins University Press; 1976: 178-218.
11. Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998;317(7168):1309-1312.
12. Harmonised Tripartite Guideline ICH. The clinical evaluation of QT/QTc interval prolongation and proa rrhythmic potential for non-antiarrhythmic drugs. May 12, 2005. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/ Guidelines/Efficacy/E14/E14-Guideline.pdf. Accessed October 22, 2012.
13. Khan A, Leventhal RM, Khan SR, et al. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol. 2002;22(1):40-45.
14. Melander H, Salmonson T, Abadie E, et al. A regulatory Apologia-a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol. 2008;18(9):623-627.
15. Kirsch I. The emperor' s new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prev Treat. 2002;5(article 23):1- 11. http://alphachoices.com/repository/assets/pdf/ EmperorsNewDrugs.pdf. Accessed January 30, 2012.
16. Hirschfeld RM, Montgomery SA, Keller MB, et al. Social functioning in depression: a review. J Clin Psychiatry. 2000;61(4):268-275.
17. Israel JA. Remission in depression: definition and initial treatment approaches. J Psychopharmacol. 2006;20(suppl):5-10.
18. Thase ME. The small specific effects of antidepressants in clinical trials: what do they mean to psychiatrists Curr Psychiatry Rep. 2011;13(6):476-482.
19. Montgomery SA, Moller HJ. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant Int Clin Psychopharmacol. 2009;24(3):111-118.
20. Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry. 2006;59(11):990-996.
21. Thase ME. Are SNRIs more effective than SSRIs a review of the current state of the controversy. Psychopharmacol Bull. 2008;41(2):58-85.
22. Nemeroff CB, Entsuah R, Benattia I, et al. Comprehensive analysis of remission (COMPARE) with venl afaxine versus SSRIs. Biol Psychiatry. 2008;63(4):424-434.
23. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746-758.
24. Guelfi JD, Ansseau M, Corruble E, et al. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. Int Clin Psychopharmacol. 1998;13(3):121-128.
25. Kasper S, Pletan Y, Solles A, et al. Comparative studies with milnacipran and tricyclic antidepressants in the trea tment of patients with major depression: a summary of clinical trial results. Int Clin Psychopharmacol. 1996; 11(suppl 4):35-39.
26. Lecrubier Y, Pletan Y, Solles A, et al. Clinical efficacy of m ilnacipran: placebo-controlled trials. Int Clin Psychopharmacol. 1996;11(suppl 4):29-33.
27. Lopez-Ibor J, Guelfi JD, Pletan Y, et al. Milnacipran and selective serotonin reuptake inhibitors in m ajor depression. Int Clin Psychopharmacol. 1996;11(suppl 4):41-46.
28. Montgomery SA, Prost JF, Solles A, et al. Efficacy and tolerability of milnacipran: an overview. Int Clin Psychopharmacol. 1996;11(suppl 4):47-51.
29. Van Amerongen AP, Ferrey G, Tournoux A. A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression. J Affect Disord. 2002;72(1):21-31.